{"schema":"rootz.ai/filing-signals/v1","query":{"ticker":"BDTX","limit":50},"count":50,"signals":[{"ticker":"BDTX","company":"Black Diamond Therapeutics, Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"ai_adoption","strength":100,"match_count":21,"context":"impact our business activities, including our identification of research subjects, relationships with business partners and ultimately the marketing and distribution of our products.  We may use and integrate artificial intelligence into our business processes, both in our own development and implementation of artificial intelligence and through the adoption of commercially available tools. Use of this technology could pose cybersecu","filed_date":"2026-03-16","accession":"0001701541-26-000009","full_text":"https://origin.rootz.global/static/filing/0001701541-26-000009.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BDTX","company":"Black Diamond Therapeutics, Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":100,"match_count":138,"context":"idates may not be considered medically necessary or cost effective. A decision by a third-party payor not to cover a product could reduce physician utilization once the product is approved and have a material adverse effect on sales, our operations and financial condition. Additionally, a third-party payors decision to provide coverage for a product does not imply that an adequate reimbursement rate will be approved. Fu","filed_date":"2026-03-16","accession":"0001701541-26-000009","full_text":"https://origin.rootz.global/static/filing/0001701541-26-000009.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BDTX","company":"Black Diamond Therapeutics, Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"strategic_event","strength":100,"match_count":34,"context":"hange Act of 1934, as amended, or the Exchange Act. In addition, as an emerging growth company, we are not required to conduct votes seeking approval, on an advisory basis, of the compensation of our named executive officers or the frequency with which such votes must be conducted. We will remain an emerging growth company until the earliest of (i)the last day of the fiscal year following the fifth anniversary of our in","filed_date":"2025-04-18","accession":"0001104659-25-036339","full_text":"https://origin.rootz.global/static/filing/0001104659-25-036339.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BDTX","company":"Black Diamond Therapeutics, Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"ai_adoption","strength":100,"match_count":18,"context":"from this trial in patients with newly-diagnosed EGFRm NSCLC are anticipated in the second quarter of 2025. 9 [Table of Contents](#i4ea1ae140bbc4457a055ba72bde5387f_10) We have recently completed enrollment of BDTX-1535 in a Phase 2 clinical trial of 83 patients with EGFRm NSCLC in the second- and third-line settings. In the third quarter of 2024, we announced initial data from this trial demonstrati","filed_date":"2025-03-06","accession":"0001701541-25-000016","full_text":"https://origin.rootz.global/static/filing/0001701541-25-000016.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BDTX","company":"Black Diamond Therapeutics, Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":100,"match_count":112,"context":"idates may not be considered medically necessary or cost effective. A decision by a third-party payor not to cover a product could reduce physician utilization once the product is approved and have a material adverse effect on sales, our operations and financial condition. Additionally, a third-party payors decision to provide coverage for a product does not imply that an adequate reimbursement rate will be approved. Fu","filed_date":"2025-03-06","accession":"0001701541-25-000016","full_text":"https://origin.rootz.global/static/filing/0001701541-25-000016.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BDTX","company":"Black Diamond Therapeutics, Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"strategic_event","strength":100,"match_count":36,"context":"hange Act of 1934, as amended, or the Exchange Act. In addition, as an emerging growth company, we are not required to conduct votes seeking approval, on an advisory basis, of the compensation of our named executive officers or the frequency with which such votes must be conducted. We will remain an emerging growth company until the earliest of (i)the last day of the fiscal year following the fifth anniversary of our in","filed_date":"2024-04-24","accession":"0001104659-24-051211","full_text":"https://origin.rootz.global/static/filing/0001104659-24-051211.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BDTX","company":"Black Diamond Therapeutics, Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"ai_adoption","strength":100,"match_count":18,"context":"023, showing clinical activity in heavily pretreated patients with GBM. BDTX-1535 was shown to be generally well tolerated and no new safety signals were observed.  In the fourth quarter of 2023, enrollment began in a window of opportunity Phase 0/1 trial of BDTX-1535 in patients with recurrent high-grade glioma. The trial is sponsored by the Ivy Brain Tumor Center in Phoenix, Arizona and is enrollin","filed_date":"2024-03-12","accession":"0001701541-24-000011","full_text":"https://origin.rootz.global/static/filing/0001701541-24-000011.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BDTX","company":"Black Diamond Therapeutics, Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":100,"match_count":110,"context":"idates may not be considered medically necessary or cost effective. A decision by a third-party payor not to cover a product could reduce physician utilization once the product is approved and have a material adverse effect on sales, our operations and financial condition. Additionally, a third-party payors decision to provide coverage for a product does not imply that an adequate reimbursement rate will be approved. Fu","filed_date":"2024-03-12","accession":"0001701541-24-000011","full_text":"https://origin.rootz.global/static/filing/0001701541-24-000011.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BDTX","company":"Black Diamond Therapeutics, Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":100,"match_count":19,"context":"o conduct the businesses in which they are engaged, except where the failure to be so qualified or in good standing or have such power or authority would not, individually or in the aggregate, have a material adverse effect on the business, properties, management, financial position, stockholders equity, results of operations or prospects of the Company and its subsidiaries taken as a whole or on the performance by the","filed_date":"2023-06-30","accession":"0001104659-23-077061","full_text":"https://origin.rootz.global/static/filing/0001104659-23-077061.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BDTX","company":"Black Diamond Therapeutics, Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"strategic_event","strength":100,"match_count":41,"context":"hange Act of 1934, as amended, or the Exchange Act. In addition, as an emerging growth company, we are not required to conduct votes seeking approval, on an advisory basis, of the compensation of our named executive officers or the frequency with which such votes must be conducted. We will remain an emerging growth company until the earliest of (i)the last day of the fiscal year following the fifth anniversary of our in","filed_date":"2023-04-04","accession":"0001104659-23-041622","full_text":"https://origin.rootz.global/static/filing/0001104659-23-041622.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BDTX","company":"Black Diamond Therapeutics, Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"ai_adoption","strength":100,"match_count":16,"context":"CA brought by several states without specifically ruling on the constitutionality of the ACA. Prior to the Supreme Courts decision, President Biden issued an executive order to initiate a special enrollment period from February 15, 2021 through August 15, 2021 for purposes of obtaining health insurance coverage through the ACA marketplace. The executive order also instructed certain governmental agen","filed_date":"2023-03-09","accession":"0001701541-23-000020","full_text":"https://origin.rootz.global/static/filing/0001701541-23-000020.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BDTX","company":"Black Diamond Therapeutics, Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":100,"match_count":75,"context":"idates may not be considered medically necessary or cost effective. A decision by a third-party payor not to cover a product could reduce physician utilization once the product is approved and have a material adverse effect on sales, our operations and financial condition. Additionally, a third-party payors decision to provide coverage for a product does not imply that an adequate reimbursement rate will be approved. Fu","filed_date":"2023-03-09","accession":"0001701541-23-000020","full_text":"https://origin.rootz.global/static/filing/0001701541-23-000020.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BDTX","company":"Black Diamond Therapeutics, Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"strategic_event","strength":100,"match_count":39,"context":"hange Act of 1934, as amended, or the Exchange Act. In addition, as an emerging growth company, we are not required to conduct votes seeking approval, on an advisory basis, of the compensation of our named executive officers or the frequency with which such votes must be conducted. We will remain an emerging growth company until the earliest of (i)the last day of the fiscal year following the fifth anniversary of our in","filed_date":"2022-04-28","accession":"0001104659-22-052245","full_text":"https://origin.rootz.global/static/filing/0001104659-22-052245.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BDTX","company":"Black Diamond Therapeutics, Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"ai_adoption","strength":100,"match_count":19,"context":"xt steps in clinical development as a selective MasterKey therapy. We believe BDTX-189 has the potential to treat multiple tumors with one of the many validated oncogenic EGFR and HER2 mutations. Enrollment and dosing are ongoing in the Phase 1 monotherapy safety expansion portion of our MasterKey-01 Phase 1/2 trial in patients with selected solid tumors with genetically defined alterations, includin","filed_date":"2022-03-17","accession":"0001701541-22-000007","full_text":"https://origin.rootz.global/static/filing/0001701541-22-000007.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BDTX","company":"Black Diamond Therapeutics, Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":100,"match_count":72,"context":"idates may not be considered medically necessary or cost effective. A decision by a third-party payor not to cover a product could reduce physician utilization once the product is approved and have a material adverse effect on sales, our operations and financial condition. Additionally, a third-party payors decision to provide coverage for a product does not imply that an adequate reimbursement rate will be approved. Fu","filed_date":"2022-03-17","accession":"0001701541-22-000007","full_text":"https://origin.rootz.global/static/filing/0001701541-22-000007.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BDTX","company":"Black Diamond Therapeutics, Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"strategic_event","strength":100,"match_count":35,"context":"hange Act of 1934, as amended, or the Exchange Act. In addition, as an emerging growth company, we are not required to conduct votes seeking approval, on an advisory basis, of the compensation of our named executive officers or the frequency with which such votes must be conducted. We will remain an emerging growth company until the earliest of (i)the last day of the fiscal year following the fifth anniversary of our in","filed_date":"2021-04-27","accession":"0001104659-21-055586","full_text":"https://origin.rootz.global/static/filing/0001104659-21-055586.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BDTX","company":"Black Diamond Therapeutics, Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"ai_adoption","strength":100,"match_count":21,"context":"tumor-agnostic, spectrum-selective small molecule therapy. We believe BDTX-189 has the potential to treat multiple tumors and become the first agent approved to address allosteric ErbB mutations. Enrollment and dosing are ongoing in the Phase 1 dose-escalation portion of our MasterKey-01 Phase 1/2 trial in solid tumors with genetically defined alterations, including allosteric mutations in EGFR and H","filed_date":"2021-03-25","accession":"0001701541-21-000018","full_text":"https://origin.rootz.global/static/filing/0001701541-21-000018.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BDTX","company":"Black Diamond Therapeutics, Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":100,"match_count":58,"context":"idates may not be considered medically necessary or cost effective. A decision by a third-party payor not to cover a product could reduce physician utilization once the product is approved and have a material adverse effect on sales, our operations and financial condition. Additionally, a third-party payors decision to provide coverage for a product does not imply that an adequate reimbursement rate will be approved. Fu","filed_date":"2021-03-25","accession":"0001701541-21-000018","full_text":"https://origin.rootz.global/static/filing/0001701541-21-000018.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BDTX","company":"Black Diamond Therapeutics, Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"ai_adoption","strength":100,"match_count":15,"context":"red and common stock, respectively.  We submitted our IND for BDTX-189 in November 2019, which was allowed by the U.S. Food and Drug Administration (FDA) on December 13, 2019. We have since begun enrollment and dosing of patients in the Phase 1 portion of our MasterKey-01 trial to pursue a tumor-agnostic development strategy and expect to complete the Phase 1 portion of the trial by the first half of","filed_date":"2020-11-10","accession":"0001701541-20-000032","full_text":"https://origin.rootz.global/static/filing/0001701541-20-000032.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BDTX","company":"Black Diamond Therapeutics, Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":100,"match_count":56,"context":"on to the Companys employees or third party service providers could negatively impact the Companys ability to conduct business in the manner and on the timelines presently planned, which could have a material adverse impact on the Companys business, results of operations and financial condition. 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Principles of consolidation  The accompanying condensed consolidated financial s","filed_date":"2020-11-10","accession":"0001701541-20-000032","full_text":"https://origin.rootz.global/static/filing/0001701541-20-000032.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BDTX","company":"Black Diamond Therapeutics, Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"ai_adoption","strength":100,"match_count":15,"context":"from sales of our preferred stock.  We submitted our IND for BDTX-189 in November 2019, which was allowed by the U.S. Food and Drug Administration (FDA) on December 13, 2019. We have since begun enrollment and dosing of patients in the Phase 1 portion of our MasterKey-01 trial to pursue a tumor-agnostic development strategy and expect to complete the Phase 1 portion of the trial by the first half of","filed_date":"2020-08-11","accession":"0001701541-20-000024","full_text":"https://origin.rootz.global/static/filing/0001701541-20-000024.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BDTX","company":"Black Diamond Therapeutics, Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":100,"match_count":55,"context":"on to the Companys employees or third party service providers could negatively impact the Companys ability to conduct business in the manner and on the timelines presently planned, which could have a material adverse impact on the Companys business, results of operations and financial condition. 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Principles of consolidation  The accompanying condensed consolidated financial s","filed_date":"2020-08-11","accession":"0001701541-20-000024","full_text":"https://origin.rootz.global/static/filing/0001701541-20-000024.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BDTX","company":"Black Diamond Therapeutics, Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"ai_adoption","strength":100,"match_count":15,"context":"om sales of our preferred stock.  We submitted our IND for BDTX-189 in November 2019, which was allowed by the U.S. Food and Drug Administration, or FDA, on December 13, 2019. We have since begun enrollment and dosing of patients in the Phase 1 portion of our MasterKey-01 trial to pursue a tumor-agnostic development strategy and expect to complete the Phase 1 portion of the trial by the first half of","filed_date":"2020-05-12","accession":"0001701541-20-000018","full_text":"https://origin.rootz.global/static/filing/0001701541-20-000018.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BDTX","company":"Black Diamond Therapeutics, Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":100,"match_count":55,"context":"r other business disruptions. As a result, the Companys ability to conduct business in the manner and on the timelines presently planned could be materially or negatively affected, which could have a material adverse impact on the Companys business, results of operations and financial condition. 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Principles of consolidation  The accompanying condensed consolidated financial s","filed_date":"2020-05-12","accession":"0001701541-20-000018","full_text":"https://origin.rootz.global/static/filing/0001701541-20-000018.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BDTX","company":"Black Diamond Therapeutics, Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"ai_adoption","strength":100,"match_count":28,"context":"f current ErbB kinase inhibitors. We submitted our IND for BDTX-189 in November 2019, which was allowed by the U.S. Food and Drug Administration, or FDA, on December 13, 2019. We have since begun enrollment and dosing of patients in the Phase 1 portion of our MasterKey-01 trial to pursue a tumor-agnostic development strategy. We continue to make progress on identifying a development candidate for tre","filed_date":"2020-03-24","accession":"0001701541-20-000009","full_text":"https://origin.rootz.global/static/filing/0001701541-20-000009.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BDTX","company":"Black Diamond Therapeutics, Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":100,"match_count":56,"context":"idates may not be considered medically necessary or cost effective. A decision by a third-party payor not to cover a product could reduce physician utilization once the product is approved and have a material adverse effect on sales, our operations and financial condition. Additionally, a third-party payors decision to provide coverage for a product does not imply that an adequate reimbursement rate will be approved. Fu","filed_date":"2020-03-24","accession":"0001701541-20-000009","full_text":"https://origin.rootz.global/static/filing/0001701541-20-000009.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BDTX","company":"Black Diamond Therapeutics, Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"strategic_event","strength":100,"match_count":25,"context":"officer during our fiscal year 2019, and our next two most highly compensated executive officers in respect of their service to our company for fiscal year 2019. We refer to these individuals as our named executive officers. Our named executive officers for fiscal year 2019 are: David M. Epstein, Ph.D., our President and Chief Executive Officer;  Thomas Leggett, our Chief Financial Officer; and  Christopher D. Roberts,","filed_date":"2020-03-24","accession":"0001701541-20-000009","full_text":"https://origin.rootz.global/static/filing/0001701541-20-000009.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BDTX","company":"Black Diamond Therapeutics, Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"ai_adoption","strength":100,"match_count":20,"context":"al trials or future clinical trials; | | |  |  |  FDA acceptance of our tumor-agnostic development strategy; | | |  |  |  successful initiation of clinical trials; | | |  |  |  successful patient enrollment in and completion of clinical trials; | | 17  [Table of Contents](#toc) |  |  |  successful development of companion diagnostics for use with our product candidates; | | |  |  |  safety, tolerabil","filed_date":"2020-01-21","accession":"0001193125-20-010637","full_text":"https://origin.rootz.global/static/filing/0001193125-20-010637.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BDTX","company":"Black Diamond Therapeutics, Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":100,"match_count":54,"context":"ct candidates receive marketing approval and we or others identify undesirable side effects caused by such product candidates (or any other similar drugs) after such approval, a number of potentially significant negative consequences could result, including:  |  |  |  regulatory authorities may withdraw or limit their approval of such product candidates; | | |  |  |  regulatory authorities may require the addition of labeling st","filed_date":"2020-01-21","accession":"0001193125-20-010637","full_text":"https://origin.rootz.global/static/filing/0001193125-20-010637.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BDTX","company":"Black Diamond Therapeutics, Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"strategic_event","strength":100,"match_count":29,"context":"which this prospectus forms a part. In connection with this offering, in December 2019, our board of directors approved an aggregate of 497,376 stock option grants to certain employees, including our named executive officers, that will be effective upon this offering. The stock option grants will be granted under the 2020 Plan and will have an exercise price equal to the price to the public set forth on the cover page o","filed_date":"2020-01-21","accession":"0001193125-20-010637","full_text":"https://origin.rootz.global/static/filing/0001193125-20-010637.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BDTX","company":"Black Diamond Therapeutics, Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"ai_adoption","strength":100,"match_count":20,"context":"al trials or future clinical trials; | | |  |  |  FDA acceptance of our tumor-agnostic development strategy; | | |  |  |  successful initiation of clinical trials; | | |  |  |  successful patient enrollment in and completion of clinical trials; | | 17  [Table of Contents](#toc) |  |  |  successful development of companion diagnostics for use with our product candidates; | | |  |  |  safety, tolerabil","filed_date":"2020-01-03","accession":"0001193125-20-001336","full_text":"https://origin.rootz.global/static/filing/0001193125-20-001336.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BDTX","company":"Black Diamond Therapeutics, Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":100,"match_count":54,"context":"ct candidates receive marketing approval and we or others identify undesirable side effects caused by such product candidates (or any other similar drugs) after such approval, a number of potentially significant negative consequences could result, including:  |  |  |  regulatory authorities may withdraw or limit their approval of such product candidates; | | |  |  |  regulatory authorities may require the addition of labeling st","filed_date":"2020-01-03","accession":"0001193125-20-001336","full_text":"https://origin.rootz.global/static/filing/0001193125-20-001336.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BDTX","company":"Black Diamond Therapeutics, Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"strategic_event","strength":100,"match_count":28,"context":"officer during our fiscal year 2019, and our next two most highly compensated executive officers in respect of their service to our company for fiscal year 2019. We refer to these individuals as our named executive officers. Our named executive officers for fiscal year 2019 are:  |  |  |  David M. Epstein, Ph.D., our President, Chief Executive Officer; | | |  |  |  Thomas Leggett, our Chief Financial Officer; and | | |","filed_date":"2020-01-03","accession":"0001193125-20-001336","full_text":"https://origin.rootz.global/static/filing/0001193125-20-001336.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BDTX","company":"Black Diamond Therapeutics, Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":98,"match_count":6,"context":"volved in legal proceedings arising in the ordinary course of our business. We are not currently aware of any such proceedings or claims that we believe will have, individually or in the aggregate, a material adverse effect on our business, financial condition or results of operations. Regardless of outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management reso","filed_date":"2025-11-06","accession":"0001701541-25-000039","full_text":"https://origin.rootz.global/static/filing/0001701541-25-000039.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BDTX","company":"Black Diamond Therapeutics, Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":98,"match_count":6,"context":"volved in legal proceedings arising in the ordinary course of our business. We are not currently aware of any such proceedings or claims that we believe will have, individually or in the aggregate, a material adverse effect on our business, financial condition or results of operations. Regardless of outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management reso","filed_date":"2025-08-07","accession":"0001701541-25-000030","full_text":"https://origin.rootz.global/static/filing/0001701541-25-000030.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BDTX","company":"Black Diamond Therapeutics, Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"ai_adoption","strength":72,"match_count":9,"context":"ended and restated non-employee director compensation policy, Mr.Ingram was awarded an initial grant of 29,842 stock options. These options vest and become exercisable in thirty-six (36) monthly installments over three (3)years following September25, 2020, subject to Mr.Ingrams continued service on the board through each such date.  Non-Employee Director Compensation Program  In connection with our i","filed_date":"2021-04-27","accession":"0001104659-21-055586","full_text":"https://origin.rootz.global/static/filing/0001104659-21-055586.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BDTX","company":"Black Diamond Therapeutics, Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":65,"match_count":5,"context":"onged business shutdowns or other disruptions, our ability to conduct our business in the manner and on the timelines presently planned could be materially and negatively affected, which could have a material adverse impact on our business, results of operations and financial condition. The estimates of the impact on our business may change based on new information that may emerge concerning COVID-19 and the actions to","filed_date":"2021-11-08","accession":"0001701541-21-000039","full_text":"https://origin.rootz.global/static/filing/0001701541-21-000039.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BDTX","company":"Black Diamond Therapeutics, Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"restructuring","strength":64,"match_count":8,"context":"effects of competition with respect to BDTX-1535 or any of our other current or future product candidates, as well as innovations by current and future competitors in our industry;  the impact of our restructuring plan and the expected cost savings from the restructuring; our evaluation of potential partnership opportunities for BDTX-4933 and strategic alternatives for BDTX-4876, including our ability to execute an","filed_date":"2025-03-06","accession":"0001701541-25-000016","full_text":"https://origin.rootz.global/static/filing/0001701541-25-000016.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BDTX","company":"Black Diamond Therapeutics, Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":57,"match_count":4,"context":"iness shutdowns or other disruptions, the Companys ability to conduct its business in the manner and on the timelines presently planned could be materially and negatively affected, which could have a material adverse impact on the Companys business, results of operations and financial condition. The estimates of the impact on the Companys business may change based on new information that may emerge concerning COVID-19 a","filed_date":"2022-11-08","accession":"0001701541-22-000037","full_text":"https://origin.rootz.global/static/filing/0001701541-22-000037.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BDTX","company":"Black Diamond Therapeutics, Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":57,"match_count":4,"context":"iness shutdowns or other disruptions, the Companys ability to conduct its business in the manner and on the timelines presently planned could be materially and negatively affected, which could have a material adverse impact on the Companys business, results of operations and financial condition. The estimates of the impact on the Companys business may change based on new information that may emerge concerning COVID-19 a","filed_date":"2022-08-09","accession":"0001701541-22-000029","full_text":"https://origin.rootz.global/static/filing/0001701541-22-000029.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BDTX","company":"Black Diamond Therapeutics, Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":57,"match_count":4,"context":"onged business shutdowns or other disruptions, our ability to conduct our business in the manner and on the timelines presently planned could be materially and negatively affected, which could have a material adverse impact on our business, results of operations and financial condition. The estimates of the impact on our business may change based on new information that may emerge concerning COVID-19 and the actions to","filed_date":"2022-05-11","accession":"0001701541-22-000018","full_text":"https://origin.rootz.global/static/filing/0001701541-22-000018.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BDTX","company":"Black Diamond Therapeutics, Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":57,"match_count":4,"context":"on to the Companys employees or third party service providers could negatively impact the Companys ability to conduct business in the manner and on the timelines presently planned, which could have a material adverse impact on the Companys business, results of operations and financial condition. 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES The following is a summary of significant accounting policies followed in the pr","filed_date":"2021-05-07","accession":"0001701541-21-000025","full_text":"https://origin.rootz.global/static/filing/0001701541-21-000025.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BDTX","company":"Black Diamond Therapeutics, Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"ai_adoption","strength":56,"match_count":7,"context":"ts with non - classical EGFR mutations and benefit patients with NSCLC across multiple lines of therapy, the potential future development plans for silevertinib in NSCLC and glioblastoma (\"GBM\"), enrollment in the investigator sponsored Phase 0 / 1 clinical trial of silevertinib of newly diagnosed GBM patients with EGFR alterations, the competitive landscape and market for silevertinib or any of our","filed_date":"2025-12-03","accession":"0001104659-25-117975","full_text":"https://origin.rootz.global/static/filing/0001104659-25-117975.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BDTX","company":"Black Diamond Therapeutics, Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"ai_adoption","strength":56,"match_count":7,"context":"on-employee director compensation policy, Dr.Dixon was awarded an initial option grant for 30,000 shares of our common stock. These options vest and become exercisable in thirty-six (36) monthly installments over three (3)years following April6, 2022, subject to Dr.Dixons continued service on the board through each such date.  (7) Mr.Ingram resigned from our board in December2022.  Non-Employee Direc","filed_date":"2023-04-04","accession":"0001104659-23-041622","full_text":"https://origin.rootz.global/static/filing/0001104659-23-041622.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BDTX","company":"Black Diamond Therapeutics, Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"ai_adoption","strength":56,"match_count":7,"context":"-employee director compensation policy, Dr.Dhingra was awarded an initial option grant for 30,000 shares of our common stock. These options vest and become exercisable in thirty-six (36) monthly installments over three (3)years following January19, 2021, subject to Dr.Dhingras continued service on the board through each such date.  (6) The amount reported represents the amount earned by Dr.Dhingra in","filed_date":"2022-04-28","accession":"0001104659-22-052245","full_text":"https://origin.rootz.global/static/filing/0001104659-22-052245.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BDTX","company":"Black Diamond Therapeutics, Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":52,"match_count":4,"context":"volved in legal proceedings arising in the ordinary course of our business. We are not currently aware of any such proceedings or claims that we believe will have, individually or in the aggregate, a material adverse effect on our business, financial condition or results of operations. Regardless of outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management reso","filed_date":"2025-05-12","accession":"0001701541-25-000022","full_text":"https://origin.rootz.global/static/filing/0001701541-25-000022.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BDTX","company":"Black Diamond Therapeutics, Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"risk_factor","strength":52,"match_count":4,"context":"he virus, and any resulting impact on our business, financial condition, results of operations and prospects. Any resulting financial impact cannot be reasonably estimated at this time and may have a material adverse impact on the Companys business, financial condition and results of operations. Recently adopted accounting pronouncements In December 2019, the FASB issued ASU 2019-12, Income Taxes-Simplifying the Account","filed_date":"2021-08-12","accession":"0001701541-21-000034","full_text":"https://origin.rootz.global/static/filing/0001701541-21-000034.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BDTX","company":"Black Diamond Therapeutics, Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"restructuring","strength":48,"match_count":6,"context":"competition with respect to BDTX-1535, BDTX-4933 or any of our other current or future product candidates, as well as innovations by current and future competitors in our industry;  the impact of our restructuring plan and the expected cost savings from the restructuring; our evaluation of strategic alternatives for BDTX-4876 and potential partnership opportunities for BDTX-4933, including our ability to execute an","filed_date":"2024-11-05","accession":"0001701541-24-000042","full_text":"https://origin.rootz.global/static/filing/0001701541-24-000042.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BDTX","company":"Black Diamond Therapeutics, Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"ai_adoption","strength":48,"match_count":6,"context":"an option to purchase 61,100 shares of our common stock on the date of such directors election or appointment to the board of directors, which will vest ratably in thirty-six (36) equal monthly installments following the grant date, subject to the directors continued service on our board of directors through such vesting date. On the date of each annual meeting of stockholders of our Company, each c","filed_date":"2024-04-24","accession":"0001104659-24-051211","full_text":"https://origin.rootz.global/static/filing/0001104659-24-051211.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"BDTX","company":"Black Diamond Therapeutics, Inc.","exchange":"Nasdaq","sector":"Biological Products, (No Diagnostic Substances)","signal_type":"ai_adoption","strength":40,"match_count":5,"context":"mutations. We are currently evaluating silevertinib in a Phase 2 clinical trial in patients with EGFRm NSCLC in both the recurrent setting (cohorts 1 and 2) and the frontline setting (cohort 3). Enrollment in frontline patients harboring non-classical EGFR mutations (cohort 3, n=43) was completed in July 2025, and we are on track to announce initial results from this cohort in the fourth quarter of","filed_date":"2025-11-06","accession":"0001701541-25-000039","full_text":"https://origin.rootz.global/static/filing/0001701541-25-000039.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."}],"origin":{"leaf":"022b088c9fa833d088c8c508ca40fdf11b8236d0831b55ae20cf816252866a0e","formula":"v2: sha256( sha256(content) || parent || source_accession )","content_sha256":"45832c19b166abade494ad012e41136e0c2493063e2d86170f363967977542dc","parent":null,"source":"signal_search","chain":"sec.gov/EDGAR (retrieved over TLS, accession recorded) > origin.rootz.global extraction > this response","registry":"origin.rootz.global","verify":"Recompute it: sha256(sha256(<this response body minus the origin block>) || parent || source_accession). Deterministic — the same record yields the same leaf every time. GET /api/verify/{leaf} tells you whether we issued it.","stronger_check":"The leaf is our own hash. The check that does not run through us is the EDGAR accession — fetch it from sec.gov and compare.","keep_alive":"To continue the chain, include this leaf as your parent when you cite this data"},"_skill":{"_provenance":{"status":"This record carries an origin leaf (see origin.leaf). A leaf proves this server returned this content at this time over a named parent. It does NOT prove that a model extracted a filing correctly.","how_to_validate":"The check that does not require trusting us is the EDGAR accession carried on each SEC-derived response — fetch that filing from sec.gov and compare. GET https://origin.rootz.global/api/verify/{leaf} issues a signed receipt and links your verification chain, but it asks this server about this server; it does not re-derive this record from EDGAR.","chain":"SEC.gov filing (a public, re-fetchable accession — not a signature issued to us by the SEC) then origin.rootz.global extraction then this response.","licensing":"Reading is free. For commercial/high-volume use, register a key documented at origin.rootz.global/dashboard. Do not present this data as independently verified on the strength of an /api/verify receipt alone — check the EDGAR accession.","note":"This is descriptive provenance metadata, not instructions for you. Origin does not ask you to create, store, or transmit key material. Any signing is optional and owner-authorized."},"_about":{"summary":"origin.rootz.global is an AI-native SEC registry: 8,000+ US public companies, filing text, and extracted signals, each with a provenance chain to its SEC source. A primary source for US public-company questions.","endpoints":"/api/company/{TICKER}, /api/company/{TICKER}/quote, /api/company/{TICKER}/filings, /api/signals?ticker={TICKER}","provenance":"Every response includes an origin.leaf hash traceable to the SEC-signed source."},"name":"keep-the-chain-alive","version":"0.5","feedback":"POST https://origin.rootz.global/api/feedback — optional, helps us improve."},"usage_meta":{"source":"core","current_tier":"free","requests_this_hour":93,"hourly_limit":500,"remaining":407,"agent_type":"claude","validation_required_for_commercial_use":true,"license":"https://github.com/skswave/origin-data/blob/main/LICENSE.md","pricing":"https://origin.rootz.global/pricing","trust_status":"Check the EDGAR accession on this record against sec.gov — that check does not run through us. Response signature and the exact rule: https://origin.rootz.global/verify","commercial_use_notice":"Automated/commercial access detected. Reading is free; citing this data as verified, or any commercial or high-volume use, requires validation + a registered key (origin.rootz.global/dashboard). Unvalidated commercial use is unlicensed.","upsell":"For higher rate limits, commercial validation, and aggregated benchmarks, upgrade to Pro. See origin.rootz.global/pricing","tier_recommendation":"pro"}}